Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

About this update from Arch Biopartners, Inc.

[{"type":"text","content":"Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)\n\n\n\n TORONTO, April 22, 2025 (GLOBE NEWSWIRE) --\n \n Arch Biopartners Inc.\n \n , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing\n \n Phase II trial evaluating LSALT peptide\n \n for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).\n \n\n With this ethics approval in place and all training and preparations complete, the clinical team at Toronto General Hospital (TGH) is now cleared to begin patient recruitment. TGH will be the seventh site to be activated globally and the second site to recruit patients in Canada.\n \n\n\n Quote from Mr. Richard Muruve, CEO Arch Biopartners:\n \n\n\n “​We are pleased to receive ethics approval from the UHN Research Ethics Board and to initiate patient recruitment at Toronto General Hospital for our CS-AKI Phase II trial. Going forward, we plan to reduce recruitment in Turkey and increase recruitment in Canada to broaden the geographic and demographic data of our trial.”\n \n\n\n About the CS-AKI Phase II Trial\n \n\n\n The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide with a recruitment target of 240 patients.\n \n\n The primary objective of the trial is to evaluate the percentage of subjects with acute kidney injury (AKI) within seven days following on-pump (heart-lung machine) cardiac surgery, defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria.\n \n\n Details of the Phase II trial, entitled “\n \n\n Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery”\n \n\n can be viewed at\n \n clinicaltrials.gov\n \n .\n \n\n\n CS-AKI and LSALT peptide\n \n\n\n CS-AKI is often caused by ischemia-reperfusion injury (IRI) that reduces blood flow (ischemia) and thus oxygen in the kid...

More updates from Arch Biopartners, Inc.